) --




) hit a new 52-week high Wednesday as it traded at $83.88 compared with its previous 52-Week high of $82.96. Shire is changing hands at $83.47 with 94,254 shares traded as of 12:31 p.m. ET. Average volume has been 417,100 shares over the past 30 days. Shire has a market cap of $15.4 billion and is part of the

health care

sector and


industry. Shares are up 14.5% year to date as of the close of trading on Tuesday.

Shire plc, together with subsidiaries, engages in the research, development, manufacture, sale, and distribution of pharmaceutical products. The company operates through two segments: Specialty Pharmaceuticals and Human Genetic Therapies. The company has a P/E ratio of 33.2, above the average drugs industry P/E ratio of 25.5 and above the S&P 500 P/E ratio of 23.4.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full

Shire Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center